You are here

Article info

Article menu

Download PDFPDF

Review
Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

Authors

  • Shi Yong Neo Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), SingaporeDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Shengli Xu Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), SingaporeDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore PubMed articlesGoogle scholar articles
  • Joni Chong Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore PubMed articlesGoogle scholar articles
  • Kong-Peng Lam Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), SingaporeSchool of Biological Sciences, Nanyang Technological University, SingaporeDepartment of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore PubMed articlesGoogle scholar articles
  • Jing Wu Department of Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan, People's Republic of ChinaDepartment of Pharmacy, Shandong Provincial Qianfoshan Hospital, Jinan, People's Republic of China PubMed articlesGoogle scholar articles

Citation

Neo SY, Xu S, Chong J, et al
Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
Journal for ImmunoTherapy of Cancer 2023;11:e006434. doi: 10.1136/jitc-2022-006434
Online issue publication 
December 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.